Jing L. Marantz

Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis

Gèrard Socié, Marie‐Pierre Caby‐Tosi, Jing L. Marantz et al. · British Journal of Haematology · 2019 · 233 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +10

Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS

Robert J. Fox, Andrew Chan, Ralf Gold et al. · Neurology Clinical Practice · 2016 · 104 citations · Full text

Life Sciences, Immunology, Pharmacology +14

Effect of delayed‐release dimethyl fumarate on no evidence of disease activity in relapsing–remitting multiple sclerosis: integrated analysis of the phase<scp>III DEFINE</scp>and<scp>CONFIRM</scp>studies

Eva Havrdová, Gavin Giovannoni, Ralf Gold et al. · European Journal of Neurology · 2017 · 58 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +15

Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing–Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies

Ralf Gold, Gavin Giovannoni, J. Theodore Phillips et al. · Neurology and Therapy · 2016 · 39 citations · Full text

Medicine, Neurology, Pharmacology +15

Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM

Óscar Fernández, Gavin Giovannoni, Robert J. Fox et al. · Clinical Therapeutics · 2017 · 28 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +14